). Furthermore, it is well-established that human gut microbiota structure recovers to a profile comparable to that found pre-antibiotics within a short period following completion of an antibiotic course 2 . Additionally, whilst poorly-explored in cirrhosis, SCFA 3 and bile acid profiles 4 reconstitute over a time course of days to weeks after antibiotic cessation in healthy rodents without any specific intervention.
If FMT directly treated HE through modulation of gut microbiota-metabonome interactions, then it would be expected that at least some of these variables would exceed baseline values post-FMT, rather than only match baseline levels at best, as shown. Adverse events associated with FMT are uncommon, but serious adverse events are described -including bacteraemia -in the non-cirrhotic population 5 ; such concerns are clearly amplified in decompensated cirrhotics, give this group's propensity to and outcomes from sepsis. Until the safety profile of FMT within cirrhotic patients has been further evaluated -and a potential mechanistic link between FMT and improvement in HE defined -then FMT remains at too early a stage to consider more widely as HE treatment.
